149 related articles for article (PubMed ID: 2121694)
1. The heterogeneity of target recognition by lymphokine-activated killer precursor cells.
Ibayashi Y; Gray JD; Golub SH; Daibo M; Yamaki T; Kawahara T; Kubota T; Hashi K
Jpn J Cancer Res; 1990 Sep; 81(9):927-35. PubMed ID: 2121694
[TBL] [Abstract][Full Text] [Related]
2. Enhanced susceptibility of cis-diamminedichloroplatinum-treated K562 cells to lysis by peripheral blood lymphocytes and lymphokine activated killer cells.
Mizutani Y; Bonavida B; Nio Y; Yoshida O
Cancer; 1993 Feb; 71(4):1313-21. PubMed ID: 7679609
[TBL] [Abstract][Full Text] [Related]
3. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.
Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA
J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174
[TBL] [Abstract][Full Text] [Related]
4. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.
Komatsu F; Kihara K
Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487
[TBL] [Abstract][Full Text] [Related]
5. Natural killer and lymphokine-activated killer activities in stomach cancer patients with special emphasis on the effect of 5-fluorouracil, adriamycin and mitomycin-C chemotherapy.
Hong WS; Kim CM; Lee JO; Kang TW; Yun TK; Kim CY
Jpn J Clin Oncol; 1990 Mar; 20(1):87-93. PubMed ID: 2108272
[TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.
Grimm EA; Mazumder A; Zhang HZ; Rosenberg SA
J Exp Med; 1982 Jun; 155(6):1823-41. PubMed ID: 6176669
[TBL] [Abstract][Full Text] [Related]
7. Depletion of NK cells with the lysosomotropic agent L-leucine methyl ester and the in vitro generation of NK activity from NK precursor cells.
Shau H; Golub SH
J Immunol; 1985 Feb; 134(2):1136-41. PubMed ID: 3871208
[TBL] [Abstract][Full Text] [Related]
8. Human pulmonary natural killer (NK) cells exhibit limited lymphokine-activated killer (LAK) activity.
Yarbrough WC; Weissler JC
Am J Respir Cell Mol Biol; 1989 Oct; 1(4):305-11. PubMed ID: 2483121
[TBL] [Abstract][Full Text] [Related]
9. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii.
Subauste CS; Dawson L; Remington JS
J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415
[TBL] [Abstract][Full Text] [Related]
10. Generation of lymphokine-activated killer cell activity from non-NK precursor cells.
Ramsdell FJ; Lindemann RA; Shau HY; Gray JD; Golub SH
Cell Immunol; 1988 Oct; 116(2):287-98. PubMed ID: 3180226
[TBL] [Abstract][Full Text] [Related]
11. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
12. Changes in natural immunity during the course of HIV-1 infection.
Brenner BG; Gryllis C; Gornitsky M; Wainberg MA
Clin Exp Immunol; 1993 Aug; 93(2):142-8. PubMed ID: 7688673
[TBL] [Abstract][Full Text] [Related]
13. Natural killer and lymphokine-activated killer cell-mediated cytotoxicity in patients with oral cancer.
Gangal SG; Tatake RJ; Krishnan N; Mukhopadhyaya R; Naik SL; Fakih AR; Rao RS
Semin Surg Oncol; 1989; 5(5):347-50. PubMed ID: 2814145
[TBL] [Abstract][Full Text] [Related]
14. Peripheral blood lymphocytes resistant to Epstein-Barr virus immortalization manifest high natural killer (NK) type activity against NK-resistant target cells.
Gosselin J; Menezes J; Mercier G; Lamoureux G; Oth D
Viral Immunol; 1990; 3(1):55-65. PubMed ID: 2153385
[TBL] [Abstract][Full Text] [Related]
15. Assay of lymphokine-activated killer activity generated from bone marrow cells of children with acute lymphoblastic leukemia.
Zhou MX; Findley HW; Davis R; Ragab AH
Blood; 1990 Jan; 75(1):160-5. PubMed ID: 2294987
[TBL] [Abstract][Full Text] [Related]
16. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
Kalland T; Belfrage H; Bhiladvala P; Hedlund G
J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
[TBL] [Abstract][Full Text] [Related]
17. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro.
Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A
Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
19. Anti-candidial activity of natural killer (NK) and lymphokine activated killer (LAK) lymphocytes in vitro.
Gülay Z; Imir T
Immunobiology; 1996 Jul; 195(2):220-30. PubMed ID: 8877398
[TBL] [Abstract][Full Text] [Related]
20. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
